Grants and Contributions:
Title:
Process Development for GMP-Grade Anti-BCMA CAR-NK Cell Manufacturing
Agreement Number:
1026523
Agreement Value:
$286,532.00
Agreement Date:
Nov 1, 2024 - Mar 31, 2026
Description:
Chimeric Antigen Receptor-T (CAR-T) therapy is a revolutionary treatment in which T-cells are genetically engineered to enhance their ability to target and destroy cancerous cells. While CAR-T therapy is highly effective in hematological tumors, it is also very expensive, is associated with significant toxicities like Cytokine Release Syndrome (CRS) and Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS), and has made little progress outside of blood cancers. To overcome these limitations, we are developing CAR-NK cells as an off-the-shelf therapy. Our preclinical studies have clearly demonstrated the potential of anti-BCMA CAR-NK cells in treating multiple myeloma. To translate these exciting results to clinical application, we will focus on developing a large-scale production process that emulates the generation of GMP-grade CAR-NK cells. The immediate goal of this project is to create Standard Operating Procedures for large-scale CAR-NK cell production and release assays, which will be transferred to a GMP facility for clinical trials in Canada.
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Location:
Ottawa, Ontario, CA K1N 6N5
Reference Number:
172-2024-2025-Q4-1026523
Agreement Type:
Grant
Report Type:
Grants and Contributions
Recipient Business Number:
119278877
Recipient Type:
Academia
Recipient's Legal Name:
University of Ottawa
Federal Riding Name:
Ottawa--Vanier--Gloucester
Federal Riding Number:
35081
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
NAICS Code:
541710